{"text_format":"3","workbook":"xlsx","n_sheets":1,"sheets":["科技成果"],"not_rendered":{"defined_names":1},"read":"whole","date_system":"1900"}

{"sheet":"科技成果","index":0,"n_rows":4,"n_cols":37,"rows_kept":4,"merged":[[0,0,0,35],[2,29,2,32]]}
["科技成果信息采集表"]
["序号","成果名称","成果简介","成果应用场景","应用场景下解决的问题和达到的效果","成果关键技术","成果描述关键词","成果完成时间","成果完成单位（机构）","合作完成单位（机构）","成果完成人","成果类型（基础研究、应用研究、技术开发和产业化、软科学）","成果属性（原始创新、国外引进消化吸收创新等）","成果体现形式（新技术、新产品、新装备等）","成果所处阶段","所属行业领域","相关专利","相关软著","相关集成电路布图设计","相关植物新品种","相关新药","相关标准","成果（课题）来源","项目课题名称","应用前景说明","拟合作方式（技术转让、技术许可、技术服务、技术咨询、委托开发、合作开发、技术入股，其他）","联系人","联系电话","联系人邮箱","资金需求","技术交易需求","空间落地需求","其他服务需求","落地北京\n意愿","是否愿意将成果公开发布到转果果平台","填报单位编码","来源"]
[null,"必填","必填","必填","必填","必填","必填","必填","必填",null,"必填",{"$nulls":3},"必填","必填",{"$nulls":6},"必填",null,null,"必填","必填","必填",null,"至少填一项"]
["样例","针对TRPML1靶点治疗神经退行性疾病的小分子激活剂","GDI-TC004项目所开发的是一类膜离子转运蛋白激活剂，通过促进细胞自噬和溶酶体的生成，可以提高细胞内异常累积蛋白和破损细胞器的降解能力，调节细胞内的稳态平衡，从而延缓神经退行性疾病的发展。该项目迄今已合成约200个化合物，通过三种不同的实验方法确认了其激动剂的作用模式且不同的方法得出相似的趋势。最优化合物比对照化合物的活性有5-20倍的提升，有望填补NCL、ALS、AD、PD等疾病未被满足的迫切临床需求。","针对TRPML1靶点治疗神经退行性疾病。","延缓神经退行性疾病的发展。有望填补NCL、ALS、AD、PD等疾病未被满足的迫切临床需求。","开发一类膜离子转运蛋白激活剂，通过促进细胞自噬和溶酶体的生成，提高细胞内异常累积蛋白和破损细胞器的降解能力，调节细胞内的稳态平衡。","TRPML1靶点；神经退行性疾病；膜离子转运蛋白激活剂；细胞自噬；溶酶体生成","2024-04","全球健康药物研发中心",null,"丁胜","应用研究","原始创新","新产品","概念","医药健康_HI03",{"$nulls":4},"1.1类新药",null,"例如全国重点实验室、北京市自然科学基金等",null,null,"技术许可","李步云","18612996226","buyun.li@ghddi.org","需要融资XXX万","提供技术咨询,技术联合研发","经开区","特许经营","经开区","否","各单位根据情况填写"]